Krazati
Focus on Primary Resistance May Improve KRAS Inhibitor Strategies in Colorectal, Pancreatic Cancer
Premium
The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.
BMS third quarter revenues increased 8 percent to $11.90 billion, with its growth portfolio now making up half of total revenues.
Amgen's Lumakras Combo Scores High Response Rate in First-Line KRAS-Mutant Colorectal Cancer
Premium
Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, Vectibix, and chemo.
Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the best treatment for brain metastases.
Jul 26, 2024
Apr 25, 2024